select article Center- vs Home-Based Cardiac Rehabilitation in Patients With Heart Failure: EXIT-HF Randomized Controlled Trial Research articleAbstract only Center- vs Home-Based Cardiac Rehabilitation in Patients With Heart Failure: EXIT-HF Randomized Controlled Trial Cristine Schmidt, Sandra Magalhães...
The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin (TTR) or pre-albumin. Characteristic patterns of echocardiography and cardiac magnetic resonance can strongly suggest the diseas...
Rowa Attar,Maan Malahfji,Clara Angulo,Duc T Nguyen,Edward A Graviss,Dipan J Shah,William A Zoghbi BACKGROUND Guidelines for echocardiographic evaluation of aortic regurgitation (AR) have not been validated against an independent quantitative standard. OBJECTIVES The aim of this study was to evalua...
肺病与心血管疾病,特别是IHD和HF独立相关,这对全因死亡率有显著影响。然而,肺部疾病患者接受冠状动脉血运重建的可能性较小。 Early Recent, Mar 04, 2019 10.1016/j.jacc.2018.11.063 05 B型利钠肽在沙库巴曲缬沙坦治疗中的作用:PARADIGM-HF试验 JACCResearch Article ...
[7].Rohde LE, Chatterjee NA, Vaduganathan M, et al. Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter- defibrillator use and heart failure cause. J Am Coll Cardiol HF 2020;8:844–55. [8].Chatterjee NA, Moorthy MV, Pester J, et al. Sudden death in pat...
[7].Rohde LE, Chatterjee NA, Vaduganathan M, et al. Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter- defibrillator use and heart failure cause. J Am Coll Cardiol HF 2020;8:844–55. [8].Chatterjee NA, Moorthy MV, Pester J, et al. Sudden death in pat...
直接口服抗凝剂是以固定剂量给药,与体重无关,但指南建议在极端体重的患者中不要使用。 Objectives This study determined the effects of dual-pathway inhibition antithrombotic regimen (rivaroxaban 2.5 mg twice daily plus aspirin 100 ...
personalized to target adverse pathways, have significantly reduced HCM mortality >10-fold from 6%/y reported early on to 0.5%/y,1,11,15,17 currently one of the lowest of all major disease-related risks to living (eg, cancer, neurological disorders, and congestive heart failure [HF])14 (...
[7].Rohde LE, Chatterjee NA, Vaduganathan M, et al. Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter- defibrillator use and heart failure cause. J Am Coll Cardiol HF 2020;8:844–55. [8].Chatterjee NA, Moorthy MV, Pester J, et al. Sudden death in pat...